Martin Zamani1, Christian Grønhøj1, David H Jensen1, Amanda F Carlander1, Tina Agander2, Katalin Kiss2, Caroline Olsen3, Louise Baandrup3, Finn C Nielsen4, Elo Andersen5, Jeppe Friborg6, Christian von Buchwald7. 1. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark. 2. Department of Pathology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark. 3. Department of Pathology, Roskilde Hospital, 4000, Roskilde, Denmark. 4. Department of Genomic Medicine, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark. 5. Department of Oncology, Herlev Hospital, 2730, Herlev, Denmark. 6. Department of Oncology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark. 7. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen East, Denmark. Electronic address: Christian.von.buchwald@regionh.dk.
Abstract
BACKGROUND: The objectives of this study were to investigate the incidence of high-risk genotypes of human papillomavirus (HPV) in tumours of patients with oropharyngeal squamous cell carcinoma (OPSCC) during an 18-year period in Eastern Denmark. METHODS: In this population-based, consecutive, semi-national registry study, all patients diagnosed with OPSCC from 2000 to 2017 in Eastern Denmark were evaluated at head and neck oncological departments at public university hospitals. Analyses included tumour characteristics (HPV-positive [HPV+] versus HPV-negative [HPV-]), age-adjusted incidence rates (AAIRs), average annual percentage change (AAPC) of OPSCC, and patient demographics. All HPV+ cases from 2011 to 2017 were genotyped. RESULTS: In total, 55% of 2169 OPSCC cases were HPV+. HPV16, HPV33, HPV35 or other types were found in 86%, 7.4%, 3.4% and 3.2% of cases, respectively. The AAIR per 100,000 of all OPSCCs was 1.8 in 2000, which increased to 5.1 in 2017 (HPV+: threefold increase, HPV-: twofold increase). The AAPC from 2000 to 2017 increased by 7% (HPV+ increased by 10% and HPV- by 4%). The median age at diagnosis for all OPSCC cases increased during the 18-year study period (HPV+: 58-61 years, p < 0.001; HPV-: 60-65 years, p < 0.001). CONCLUSION: We report a threefold increase in OPSCC incidence during the 18-year observation period and a significant increase in median age at diagnosis. Over 93% of HPV genotypes in HPV+ OPSCC are included in current HPV vaccines except for HPV35 (4%). HPV vaccination of both sexes is advised to halt this emerging cancer epidemic.
BACKGROUND: The objectives of this study were to investigate the incidence of high-risk genotypes of human papillomavirus (HPV) in tumours of patients with oropharyngeal squamous cell carcinoma (OPSCC) during an 18-year period in Eastern Denmark. METHODS: In this population-based, consecutive, semi-national registry study, all patients diagnosed with OPSCC from 2000 to 2017 in Eastern Denmark were evaluated at head and neck oncological departments at public university hospitals. Analyses included tumour characteristics (HPV-positive [HPV+] versus HPV-negative [HPV-]), age-adjusted incidence rates (AAIRs), average annual percentage change (AAPC) of OPSCC, and patient demographics. All HPV+ cases from 2011 to 2017 were genotyped. RESULTS: In total, 55% of 2169 OPSCC cases were HPV+. HPV16, HPV33, HPV35 or other types were found in 86%, 7.4%, 3.4% and 3.2% of cases, respectively. The AAIR per 100,000 of all OPSCCs was 1.8 in 2000, which increased to 5.1 in 2017 (HPV+: threefold increase, HPV-: twofold increase). The AAPC from 2000 to 2017 increased by 7% (HPV+ increased by 10% and HPV- by 4%). The median age at diagnosis for all OPSCC cases increased during the 18-year study period (HPV+: 58-61 years, p < 0.001; HPV-: 60-65 years, p < 0.001). CONCLUSION: We report a threefold increase in OPSCC incidence during the 18-year observation period and a significant increase in median age at diagnosis. Over 93% of HPV genotypes in HPV+ OPSCC are included in current HPV vaccines except for HPV35 (4%). HPV vaccination of both sexes is advised to halt this emerging cancer epidemic.
Authors: Anders Christensen; Christian Grønhøj; Jakob Schmidt Jensen; Giedrius Lelkaitis; Katalin Kiss; Karina Juhl; Birgitte Wittenborg Charabi; Jann Mortensen; Andreas Kjær; Christian Von Buchwald Journal: Oncol Rep Date: 2022-07-01 Impact factor: 4.136
Authors: Jordi Rubió-Casadevall; Elna Ciurana; Montserrat Puigdemont; Arantza Sanvisens; Jordi Marruecos; Josefina Miró; Antoni Urban; Rosa-Lisset Palhua; Ferran Martín-Romero; Maria Rosa Ortiz-Duran; Rafael Marcos-Gragera Journal: Int J Environ Res Public Health Date: 2022-04-15 Impact factor: 4.614
Authors: Susanne I Scott; Anne Kathrine Ø Madsen; Niclas Rubek; Birgitte W Charabi; Irene Wessel; Sara Fredslund Hadjú; Claus V Jensen; Sarah Stephen; Joanne M Patterson; Jeppe Friborg; Kathrine A Hutcheson; Henrik Kehlet; Christian von Buchwald Journal: Cancer Med Date: 2020-12-04 Impact factor: 4.452
Authors: Kathrine Kronberg Jakobsen; Amanda-Louise Fenger Carlander; Simone Kloch Bendtsen; Martin Garset-Zamani; Charlotte Duch Lynggaard; Christian Grønhøj; Christian von Buchwald Journal: Viruses Date: 2021-08-26 Impact factor: 5.048